Pfizer new antiviral

Protectors from hospitalisation, the story so far. Oral meds than can be prescribed from home with onset of symptoms Molnupiravir, approved by MHRA https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra The antiviral was found to be safe and effective following a stringent review of the available evidence. https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/ Public domain data, Merck press release $ 700 per 5-day course Under 50% reduction in deuteriation Effect of early treatment with fluvoxamine Together Trial group Public domain data, Peer reviewed trial in the Lancet https://clinicaltrials.gov/ct2/show/NCT04727424 https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext Adults with a risk factor $4 for a 10-day course 32% protection against hospitalization 32% protection against death Fluvoxamine is approved by the Food and Drug Administration as an antidepressant Doctors already can prescribe it off-label — using their clinical judgment https://www.washingtonpost.com/science/2021/10/28/antidepressant-fluvoxamine-coronavirus-lancet/? https://bnf.nice.org.uk/drug/fluvoxamine-maleate.html https://www.togethertrial.com Ivermectin, Together trial results not yet released PFIZER’S NOVEL COVID-19 ORAL ANTIVIRAL TREATMENT CANDIDATE REDUCED RISK OF HOSPITALIZATION OR DEATH BY 89% IN INTERIM ANALYSIS OF PHASE 2/3 EPIC-HR STUDY https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate Public domain data, Pfizer press release PAXLOVID™ (PF-07321332; ritonavir) Found to reduce the risk of hospitalization or death by 89% Compared to placebo in non-hospitalized high-risk adults with COVID-19 Through Day 28 PAXLOVID group No deaths Placebo group 10 deaths Pfizer plans to submit the data as part of its ongoing rolling submission to the U.S. FDA for Emergency Use Authorization (EUA) as soon as possible Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) Randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness Scheduled interim analysis 89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placebo In patients treated within 3 days of symptom onset PAXLOVID group 0.8% of patients hospitalized 3/389 hospitalized with no deaths Placebo group 7.0% of patients hospitalized or died 27/385 hospitalized with 7 subsequent deaths (p less than 0.0001) 1 in 10,000 chance In patients treated within 5 days of symptom onset PAXLOVID group 1.0% of patients hospitalized 6/607 hospitalized with no deaths Placebo group 6. 7% of patients hospitalized or died 41/612 hospitalized, with 10 subsequent deaths p less than 0.0001 At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (FDA), Pfizer will cease further enrollment into the study due to the overwhelming efficacy demonstrated in these results About the Phase 2/3 EPIC-HR Study Interim Analysis 1,219 adults enrolled out of 3,000 planned North and South America, Europe, Africa, and Asia Enrolled individuals had a laboratory-confirmed diagnosis of SARS-CoV-2 infection Mild to moderate symptoms At least one characteristic or underlying medical condition Randomized (1:1) to receive PAXLOVID™ or placebo orally every 12 hours for five days About the Phase 2/3 EPIC-HR Study Safety Data Safety data, n = 1881 Treatment-emergent adverse events PAXLOVID™group 19% Placebo group 21% Most of which were mild in intens Learn more about your ad choices. Visit megaphone.fm/adchoices